Sanofi India Limited
Featured Analysts
The India for India plan is a strategy for Sanofi India, aligning with global strategies. Localization of supply is particularly relevant for India, leveraging the strong industrial footprint in the pharma industry. We have a significant plant in Goa and work with contract manufacturers for both local and export needs. This strategy emphasizes local production and innovations, which makes sense for India but not necessarily for other markets.
The partnerships with Cipla and Emcure are aimed at expanding our reach and accelerating growth. Both companies will handle the distribution and promotion of these brands.
The marketing will be done by the partners. The partner is doing the distribution and the marketing. Both.
The model is mainly gross to net where the partner is in charge of distribution and marketing. We are booking net sales in our books. The impact is accretive value for shareholders, improving operating profit based on the net present value evaluated for this project.
We don't disclose MR numbers. However, the field force promoting these brands will be from the partners, which is larger than what we had. The partnerships tap into a larger sales force for better distribution and promotion.
We operate in key categories like allergy, physical wellness, and pain. Most of our launches will focus on these core categories.
This is an extremely complementary launch. Sanofi has only played in the basal insulin market until now. With Soliqua, we tap into the premix insulin segment where we were not competing. Soliqua addresses a different need that we were not catering to before, offering a best-in-class product with clear superiority over many alternatives. We anticipate Soliqua to quickly gain significant market share as healthcare professionals upgrade their patients to this treatment. Soliqua captures patients who were previously not addressed by our portfolio, making it beneficial for patients, healthcare professionals, and Sanofi.
The difference in headcount measurement between 2022 and 2023 is important. In 2022, we counted employees based on their work duration throughout the year, while in 2023, we count only those employed at the end of the year. This change in methodology accounts for the reduction in numbers.
The vision for the consumer healthcare (CHC) business is to bring health into people's hands and become the best FMCG company globally. We will evaluate good global portfolios for future launches in India while also leveraging opportunities within our current portfolio.
The deal is signed between Sanofi India and these companies, and it is a distribution and promotion agreement, not an out-licensing deal. Sanofi continues to own, manufacture, and book sales on these brands.
The regulations are still in draft stage, and OTC companies are working with the government to finalize them. Once implemented, these regulations could modernize the OTC market in India, allowing for better distribution and consumer engagement, similar to other markets.
The market size for Soliqua is around INR 1,000 crores. However, we do not provide forward-looking estimates for specific brands. We are focused on expanding our diabetes portfolio in the coming years.
Total insulin market share is 8%. In basal insulin, we have about 38%. We had zero in premix, but now with Soliqua, we believe it can achieve leadership in that segment.